Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Beneficial effects of intraovarian injection of platelet-rich plasma in women with poor ovarian response

  • Aida Najafian (Department of Infertility, Shariati Hospital, Tehran University of Medical Science) ;
  • Ashraf Alyasin (Department of Obstetrics and Gynecology and Female Infertility Unit, Tehran University of Medical Sciences) ;
  • Marziyeh Aghahosseini (Department of Obstetrics and Gynecology and Female Infertility Unit, Tehran University of Medical Sciences) ;
  • Sedigheh Hosseinimousa (Department of Obstetrics and Gynecology and Female Infertility Unit, Tehran University of Medical Sciences) ;
  • Seyyedeh Neda Kazemi (Department of Obstetrics and Gynecology and Female Infertility Unit, Tehran University of Medical Sciences)
  • Received : 2023.04.22
  • Accepted : 2023.07.19
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Infertility can result from a diminished ovarian reserve, but a potential remedy exists in the form of platelet-rich plasma (PRP) administration. This treatment involves both biological factors and tissue trauma mechanisms, which stimulate folliculogenesis, making it a promising and effective strategy. We assessed the impact of direct PRP injections into the ovaries on the fertility outcomes of women classified as poor responders. Methods: A quasi-experimental study was conducted from April 2021 to December 2022, focusing on patients classified as POSEIDON grade 3 or 4. PRP injections were administered into both ovaries. After 3 months, data were collected on anti-Mullerian hormone (AMH) level, follicle-stimulating hormone (FSH) level, and the numbers of oocytes, mature oocytes, and good-quality embryos following ovarian stimulation. We then compared the data from before and after PRP injection. Results: This study included 50 women, with a mean of 39 years (interquartile range [IQR], 35 to 43) and 4 years (IQR, 2 to 6) for age and infertility duration, respectively. FSH levels decreased after treatment, while AMH levels and the numbers of oocytes, metaphase II oocytes, and high-quality embryos increased. However, only the increase in high-quality embryos was significant. The pregnancy and spontaneous pregnancy rates were 20% and 14%, respectively. Notably, women with secondary infertility exhibited a significantly higher pregnancy rate than those with primary infertility. Conclusion: Ample evidence suggests that PRP can enhance ovarian function. However, further studies are needed to identify the appropriate candidates for this procedure, establish the optimal PRP preparation method, and standardize the procedure for its adjuvant use in assisted reproductive technology cycles.

Keywords

References

  1. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589. Fertil Steril 2014;101:633-4. https://doi.org/10.1016/j.fertnstert.2013.12.032
  2. May-Panloup P, Boucret L, Chao de la Barca JM, Desquiret-Dumas V, Ferre-L'Hotellier V, Moriniere C, et al. Ovarian ageing: the role of mitochondria in oocytes and follicles. Hum Reprod Update 2016;22:725-43. https://doi.org/10.1093/humupd/dmw028
  3. Wang S, Zheng Y, Li J, Yu Y, Zhang W, Song M, et al. Single-cell transcriptomic atlas of primate ovarian aging. Cell 2020;180:585-600. https://doi.org/10.1016/j.cell.2020.01.009
  4. Poseidon Group (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number); Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril 2016;105:1452-3. https://doi.org/10.1016/j.fertnstert.2016.02.005
  5. Kuang X, Tang Y, Xu H, Ji M, Lai D. The evaluation of ovarian function recovery following treatment of primary ovarian insufficiency: a systematic review. Front Endocrinol (Lausanne) 2022;13:855992.
  6. Tandulwadkar S, Karthick MS. Combined use of autologous bone marrow-derived stem cells and platelet-rich plasma for ovarian rejuvenation in poor responders. J Hum Reprod Sci 2020;13:184-90. https://doi.org/10.4103/jhrs.JHRS_130_19
  7. Samadi P, Sheykhhasan M, Khoshinani HM. The use of platelet-rich plasma in aesthetic and regenerative medicine: a comprehensive review. Aesthetic Plast Surg 2019;43:803-14. https://doi.org/10.1007/s00266-018-1293-9
  8. Pantos K, Nitsos N, Kokkali G, Vaxevanoglou T, Markomichali C, Pantou A, et al. Ovarian rejuvenation and folliculogenesis reactivation in peri-menopausal women after autologous platelet-rich plasma treatment. Hum Reprod 2016;31(Suppl 1):i301.
  9. Seckin S, Ramadan H, Mouanness M, Kohansieh M, Merhi Z. Ovarian response to intraovarian platelet-rich plasma (PRP) administration: hypotheses and potential mechanisms of action. J Assist Reprod Genet 2022;39:37-61. https://doi.org/10.1007/s10815-021-02385-w
  10. Marchante M, Buigues A, Ramirez-Martin N, Martinez J, Pellicer N, Pellicer A, et al. Single intraovarian dose of stem cell- and platelet-secreted factors mitigates age-related ovarian infertility in a murine model. Am J Obstet Gynecol 2023;228:561.
  11. Moulavi F, Akram RT, Khorshid Sokhangouy S, Hosseini SM. Platelet rich plasma efficiently substitutes the beneficial effects of serum during in vitro oocyte maturation and helps maintain the mitochondrial activity of maturing oocytes. Growth Factors 2020;38:152-66. https://doi.org/10.1080/08977194.2021.1900168
  12. Nishina H. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis. Cancer Sci 2022;113:1900-8. https://doi.org/10.1111/cas.15352
  13. Cakiroglu Y, Yuceturk A, Karaosmanoglu O, Kopuk SY, Korun ZE, Herlihy N, et al. Ovarian reserve parameters and IVF outcomes in 510 women with poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP). Aging (Albany NY) 2022;14:2513-23. https://doi.org/10.18632/aging.203972
  14. Sills ES, Wood SH. Progress in human ovarian rejuvenation: current platelet-rich plasma and condensed cytokine research activity by scope and international origin. Clin Exp Reprod Med 2021;48:311-5. https://doi.org/10.5653/cerm.2021.04651
  15. Farimani M, Nazari A, Mohammadi S, Aliabad RA. Correction to: evaluation of intra-ovarian platelet-rich plasma administration on oocytes-dependent variables in patients with poor ovarian response: a retrospective study according to the POSEIDON criteria. Reprod Biol Endocrinol 2021;19:169.
  16. Navali N, Sadeghi L, Farzadi L, Ghasemzadeh A, Hamdi K, Hakimi P, et al. Intraovarian injection of autologous platelet-rich plasma improves therapeutic approaches in the patients with poor ovarian response: a before-after study. Int J Fertil Steril 2022;16:90-4.
  17. Merhi Z, Seckin S, Mouanness M. Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization. Clin Exp Reprod Med 2022;49:210-4. https://doi.org/10.5653/cerm.2021.05057
  18. Hosseini L, Shirazi A, Naderi MM, Shams-Esfandabadi N, Borjian Boroujeni S, Sarvari A, et al. Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. Reprod Biomed Online 2017;35:343-50. https://doi.org/10.1016/j.rbmo.2017.04.007
  19. Stojkovska S, Dimitrov G, Stamenkovska N, Hadzi-Lega M, Petanovski Z. Live birth rates in poor responders' group after previous treatment with autologous platelet-rich plasma and low dose ovarian stimulation compared with poor responders used only low dose ovarian stimulation before in vitro fertilization. Open Access Maced J Med Sci 2019;7:3184-8. https://doi.org/10.3889/oamjms.2019.825
  20. Nelson LM. Clinical practice: primary ovarian insufficiency. N Engl J Med 2009;360:606-14. https://doi.org/10.1056/NEJMcp0808697
  21. Aflatoonian A, Lotfi M, Saeed L, Tabibnejad N. Effects of intraovarian injection of autologous platelet-rich plasma on ovarian rejuvenation in poor responders and women with primary ovarian insufficiency. Reprod Sci 2021;28:2050-9. https://doi.org/10.1007/s43032-021-00483-9
  22. Skinner MK. Encyclopedia of reproduction. 2nd ed. Elsevier AP; 2018.
  23. Melo P, Navarro C, Jones C, Coward K, Coleman L. The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study. J Assist Reprod Genet 2020;37:855-63. https://doi.org/10.1007/s10815-020-01710-z
  24. Barad DH, Albertini DF, Molinari E, Gleicher N. Preliminary report of intraovarian injections of autologous platelet-rich plasma (PRP) in extremely poor prognosis patients with only oocyte donation as alternative: a prospective cohort study. Hum Reprod Open 2022;2022:hoac027.